Provided herein are compositions and methods for vaccinating against infection with pathogenic Escherichia coli (E. coli). In some embodiments, the compositions may include a vaccine including an immunogenic portion of at least two E. coli proteins described herein.

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.

The present invention discloses a hypericin albumin nanoparticle-Escherichia coli serum antibody complex, which is obtained through adding mixed hypericin albumin nanoparticles and rabbit anti-Escherichia colis into ethanediol, irradiating them with carbon ion, setting them at a low temperature for 2 hours after irradiation, centrifuging them at a low temperature, and freezing and drying the precipitates. Its preparation method and application are also provided. The beneficial effects of the present invention are as follows: the present invention provides a hypericin albumin nanoparticle-Escherichia coli serum antibody complex and its preparation method and application, wherein through bacteriostatic test and clinical pharmacodynamic test, it is proved that the effects of target complex is greatly improved compared with that of the prior drug, because the Escherichia coli serum antibodies seek and capture Escherichia coli and the hypericin albumin nanoparticles inhibit and kill Escherichia coli, which precisely attacks Escherichia coli and strengthen the antibacterial effect of hypericin albumin nanoparticle on chicken focus location.

The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.

The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O5 polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition.

Disclosed is an immunogenic formulation that induces protection against Shiga Toxin-Producing Escherichia coli (STEC), the formulation comprising: one or more chimeric proteins derived wholly or in part from OmpT and Hes proteins of STEC; and at least one physiologically or pharmaceutically acceptable excipient, carrier and/or diluent.

The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—U.sub.x+4—U.sub.x+3—U.sub.x+2—U.sub.x+1—U.sub.x).sub.m—(V.sub.x+2—V.sub.x+1—V.sub.x).sub.1-m-T-O-L-E that is related to Klebsiella pneumoniae serotype O3, O3b and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae serotype O3, O3b and/or O5 bacteria.

The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.